|
FR901228A
(fr)
|
1943-01-16 |
1945-07-20 |
Deutsche Edelstahlwerke Ag |
Système d'aimant à entrefer annulaire
|
|
US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
|
US4261989A
(en)
|
1979-02-19 |
1981-04-14 |
Kaken Chemical Co. Ltd. |
Geldanamycin derivatives and antitumor drug
|
|
US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
US4851332A
(en)
|
1985-04-01 |
1989-07-25 |
Sloan-Kettering Institute For Cancer Research |
Choriocarcinoma monoclonal antibodies and antibody panels
|
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US5114946A
(en)
|
1987-06-12 |
1992-05-19 |
American Cyanamid Company |
Transdermal delivery of pharmaceuticals
|
|
US4818541A
(en)
|
1987-08-19 |
1989-04-04 |
Schering Corporation |
Transdermal delivery of enantiomers of phenylpropanolamine
|
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
AU6290090A
(en)
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
CA2078539C
(en)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Process for producing humanized chimera antibody
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
ES2102007T3
(es)
|
1992-01-23 |
1997-07-16 |
Merck Patent Gmbh |
Proteinas de fusion de fragmentos de anticuerpo monomeras y dimeras.
|
|
WO1993016185A2
(en)
|
1992-02-06 |
1993-08-19 |
Creative Biomolecules, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US5646253A
(en)
|
1994-03-08 |
1997-07-08 |
Memorial Sloan-Kettering Cancer Center |
Recombinant human anti-LK26 antibodies
|
|
AU675223B2
(en)
|
1992-05-08 |
1997-01-30 |
Creative Biomolecules, Inc. |
Chimeric multivalent protein analogues and methods of use thereof
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
EP0672068A4
(en)
|
1992-09-25 |
1997-02-26 |
Commw Scient Ind Res Org |
TARGET MOLECULES BINDING POLYPEPTIDES.
|
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
|
WO1994009817A1
(en)
|
1992-11-04 |
1994-05-11 |
City Of Hope |
Novel antibody construct
|
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
|
JP3720353B2
(ja)
|
1992-12-04 |
2005-11-24 |
メディカル リサーチ カウンシル |
多価および多重特異性の結合タンパク質、それらの製造および使用
|
|
US5504048A
(en)
|
1993-06-02 |
1996-04-02 |
Fina Technology, Inc. |
Addition of lithium compounds to Ziegler-Natta catalysts for increased molecular weight in polyolefins
|
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
|
EP0679660A4
(en)
|
1993-11-16 |
2000-08-16 |
Pola Chem Ind Inc |
MONOCLONAL ANTIBODY AGAINST HUMAN TYROSINASE
|
|
US5635388A
(en)
|
1994-04-04 |
1997-06-03 |
Genentech, Inc. |
Agonist antibodies against the flk2/flt3 receptor and uses thereof
|
|
WO1995029193A2
(en)
|
1994-04-22 |
1995-11-02 |
The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services |
Melanoma antigens
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
JP3659261B2
(ja)
|
1994-10-20 |
2005-06-15 |
モルフォシス・アクチェンゲゼルシャフト |
組換体タンパク質の多機能性複合体への標的化ヘテロ結合
|
|
JP3066983B2
(ja)
|
1995-01-18 |
2000-07-17 |
ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング |
膜結合ｃｄ３０抗原の蛋白質分解性開裂及び遊離を防ぐ抗ｃｄ３０抗体
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
ATE274064T1
(de)
|
1995-05-23 |
2004-09-15 |
Morphosys Ag |
Multimere proteine
|
|
WO1997014719A1
(en)
|
1995-10-16 |
1997-04-24 |
Unilever N.V. |
A bifunctional or bivalent antibody fragment analogue
|
|
JP2000505787A
(ja)
|
1996-01-05 |
2000-05-16 |
アメリカ合衆国 |
中皮抗原及びそれを標的化するための方法及びキット
|
|
DE19608769C1
(de)
|
1996-03-07 |
1997-04-10 |
Univ Eberhard Karls |
Antikörper BV10A4H2
|
|
WO1997038102A1
(en)
|
1996-04-04 |
1997-10-16 |
Unilever Plc |
Multivalent and multispecific antigen-binding protein
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
DE69703121D1
(de)
|
1996-10-25 |
2000-10-19 |
Us Health |
Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
|
|
AU7266698A
(en)
|
1997-04-30 |
1998-11-24 |
Enzon, Inc. |
Polyalkylene oxide-modified single chain polypeptides
|
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
EP1012280B1
(en)
|
1997-06-11 |
2004-11-10 |
Borean Pharma A/S |
Trimerising module
|
|
WO1999023221A2
(en)
|
1997-10-27 |
1999-05-14 |
Unilever Plc |
Multivalent antigen-binding proteins
|
|
ES2255194T3
(es)
|
1997-12-01 |
2006-06-16 |
The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services |
Anticuerpos, que incluyen moleculas fv, e inmunoconjugados que presentan una afinidad de enlace elevada para la mesotelina y metodos para su utilizacion.
|
|
PT1049787E
(pt)
|
1998-01-23 |
2005-04-29 |
Vlaams Interuniv Inst Biotech |
Derivados de anticorpos multipropositos
|
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6803448B1
(en)
|
1998-07-22 |
2004-10-12 |
Vanderbilt University |
GBS toxin receptor
|
|
WO2000006605A2
(en)
|
1998-07-28 |
2000-02-10 |
Micromet Ag |
Heterominibodies
|
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
|
IL143236A0
(en)
|
1998-12-16 |
2002-04-21 |
Warner Lambert Co |
Treatment of arthritis with mek inhibitors
|
|
US6528481B1
(en)
|
1999-02-16 |
2003-03-04 |
The Burnam Institute |
NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
PL211786B1
(pl)
|
1999-08-17 |
2012-06-29 |
Apoxis Sa |
Zastosowanie przeciwciała oraz polipeptydu
|
|
DE60038252T2
(de)
|
1999-09-30 |
2009-03-19 |
Kyowa Hakko Kogyo Co., Ltd. |
Menschlicher Antikörper gegen Gangliosid GD3 für die Transplantationskomplentarität bestimmende Region und Derivate des Antikörpers gegen das Gangliosid GD3
|
|
CA2393126C
(en)
|
1999-11-29 |
2016-05-24 |
The Trustees Of Columbia University In The City Of New York |
Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
|
|
EP1234031B2
(en)
|
1999-11-30 |
2021-11-24 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
EP2329847B1
(en)
|
2000-03-06 |
2016-11-02 |
University of Kentucky Research Foundation |
Use of an antibody or an immunotoxin that selectively binds to cd123 to impair hematologic cancer progenitor cells
|
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
|
AU2001264946A1
(en)
|
2000-05-24 |
2001-12-03 |
Imclone Systems Incorporated |
Bispecific immunoglobulin-like antigen binding proteins and method of production
|
|
WO2002002781A1
(en)
|
2000-06-30 |
2002-01-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
|
WO2002006213A2
(en)
|
2000-07-19 |
2002-01-24 |
Warner-Lambert Company |
Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
|
|
AU2001283496A1
(en)
|
2000-07-25 |
2002-02-05 |
Immunomedics, Inc. |
Multivalent target binding protein
|
|
US7718600B2
(en)
|
2000-09-29 |
2010-05-18 |
The Trustees Of Princeton University |
IAP binding compounds
|
|
JP4261907B2
(ja)
|
2000-10-20 |
2009-05-13 |
中外製薬株式会社 |
低分子化アゴニスト抗体
|
|
US7090843B1
(en)
|
2000-11-28 |
2006-08-15 |
Seattle Genetics, Inc. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
AU2002247826A1
(en)
|
2001-03-13 |
2002-09-24 |
University College London |
Specific binding members
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
US6770622B2
(en)
|
2001-06-08 |
2004-08-03 |
Gary A. Jarvis |
N-terminally truncated galectin-3 for use in treating cancer
|
|
AU2002319402B2
(en)
|
2001-06-28 |
2008-09-11 |
Domantis Limited |
Dual-specific ligand and its use
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
NZ531294A
(en)
*
|
2001-08-06 |
2005-11-25 |
Childrens Medical Center |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
ES2736165T3
(es)
|
2001-08-23 |
2019-12-26 |
Rsr Ltd |
Regiones epítopo de un receptor de tirotropina (TSH), sus usos y anticuerpos para las mismas
|
|
ES2276735T3
(es)
|
2001-09-14 |
2007-07-01 |
Affimed Therapeutics Ag |
Anticuerpos fv multimericos de cadena sencilla en tandem.
|
|
AU2002351239A1
(en)
|
2001-12-04 |
2003-06-17 |
Dana-Farber Cancer Institute, Inc. |
Antibody to latent membrane proteins and uses thereof
|
|
WO2003049684A2
(en)
|
2001-12-07 |
2003-06-19 |
Centocor, Inc. |
Pseudo-antibody constructs
|
|
BR0307544A
(pt)
|
2002-02-01 |
2004-12-07 |
Ariad Gene Therapeutics Inc |
Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
|
|
AU2003209446B2
(en)
|
2002-03-01 |
2008-09-25 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
US7799827B2
(en)
|
2002-03-08 |
2010-09-21 |
Eisai Co., Ltd. |
Macrocyclic compounds useful as pharmaceuticals
|
|
EP1500665B1
(en)
|
2002-04-15 |
2011-06-15 |
Chugai Seiyaku Kabushiki Kaisha |
METHODS FOR CONSTRUCTING scDb LIBRARIES
|
|
TWI275390B
(en)
|
2002-04-30 |
2007-03-11 |
Wyeth Corp |
Process for the preparation of 7-substituted-3- quinolinecarbonitriles
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
PT1537878E
(pt)
|
2002-07-03 |
2010-11-18 |
Ono Pharmaceutical Co |
Composições de imunopotenciação
|
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
CN1787837A
(zh)
|
2002-11-15 |
2006-06-14 |
希龙公司 |
防止和治疗癌转移以及与癌转移相关的骨质损失的方法
|
|
JP4744147B2
(ja)
|
2002-11-26 |
2011-08-10 |
ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー |
アフィニティー精製抗体を用いた甲状腺刺激ホルモン受容体自己抗体の同定
|
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
|
CA2512000C
(en)
|
2002-12-26 |
2011-08-09 |
Eisai Co., Ltd. |
Selective estrogen receptor modulator
|
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
|
WO2004087758A2
(en)
|
2003-03-26 |
2004-10-14 |
Neopharm, Inc. |
Il 13 receptor alpha 2 antibody and methods of use
|
|
US20050003403A1
(en)
|
2003-04-22 |
2005-01-06 |
Rossi Edmund A. |
Polyvalent protein complex
|
|
EP1646357A4
(en)
|
2003-06-27 |
2007-01-10 |
Diadexus Inc |
PRO104 ANTIBODY COMPOSITIONS AND APPLICATION PROCEDURES
|
|
US7700097B2
(en)
|
2003-06-27 |
2010-04-20 |
Biogen Idec Ma Inc. |
Purification and preferential synthesis of binding molecules
|
|
EP1638510B1
(en)
|
2003-07-01 |
2015-09-02 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
|
WO2005014652A1
(en)
|
2003-08-05 |
2005-02-17 |
Morphotek, Inc. |
A variant cell surface molecule associated with cancer
|
|
US7399865B2
(en)
|
2003-09-15 |
2008-07-15 |
Wyeth |
Protein tyrosine kinase enzyme inhibitors
|
|
AU2004279742A1
(en)
|
2003-10-08 |
2005-04-21 |
Kyowa Hakko Kirin Co., Ltd. |
Fused protein composition
|
|
JPWO2005035577A1
(ja)
|
2003-10-08 |
2007-11-22 |
協和醗酵工業株式会社 |
ガングリオシドｇｄ３に特異的に結合する抗体組成物
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
US20050136051A1
(en)
|
2003-12-22 |
2005-06-23 |
Bernard Scallon |
Methods for generating multimeric molecules
|
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
|
AU2005205533B2
(en)
|
2004-01-07 |
2012-03-22 |
Novartis Vaccines And Diagnostics, Inc. |
M-CSF-specific monoclonal antibody and uses thereof
|
|
CA2553871A1
(en)
|
2004-01-16 |
2005-08-04 |
The Regents Of The University Of Michigan |
Smac peptidomimetics and the uses thereof
|
|
MXPA06008095A
(es)
|
2004-01-16 |
2007-03-28 |
Univ Michigan |
Mimeticos de smac conformacionalmente restringidos y sus usos.
|
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
|
AU2005235811B2
(en)
|
2004-02-06 |
2011-11-03 |
Morphosys Ag |
Anti-CD38 human antibodies and uses therefor
|
|
CA2558615C
(en)
|
2004-03-23 |
2013-10-29 |
Genentech, Inc. |
Azabicyclo-octane inhibitors of iap
|
|
RS52545B
(sr)
|
2004-04-07 |
2013-04-30 |
Novartis Ag |
Inhibitori protein apoptoze (iap)
|
|
MXPA06014065A
(es)
|
2004-06-01 |
2007-01-31 |
Genentech Inc |
Conjugados de droga-anticuerpo y metodos.
|
|
CA2570321C
(en)
|
2004-07-02 |
2013-10-08 |
Genentech, Inc. |
Inhibitors of iap
|
|
WO2006010118A2
(en)
|
2004-07-09 |
2006-01-26 |
The Regents Of The University Of Michigan |
Conformationally constrained smac mimetics and the uses thereof
|
|
BRPI0513310A
(pt)
|
2004-07-12 |
2008-05-06 |
Idun Pharmaceuticals Inc |
análogos de tetrapeptìdeo
|
|
WO2006020060A2
(en)
|
2004-07-15 |
2006-02-23 |
Tetralogic Pharmaceuticals Corporation |
Iap binding compounds
|
|
WO2006020258A2
(en)
|
2004-07-17 |
2006-02-23 |
Imclone Systems Incorporated |
Novel tetravalent bispecific antibody
|
|
CA2577082A1
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
US7999077B2
(en)
|
2004-09-30 |
2011-08-16 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
IRTA2 antibodies and methods of use
|
|
WO2006042104A2
(en)
|
2004-10-04 |
2006-04-20 |
Regents Of The University Of Minnesota |
Calixarene-based peptide conformation mimetics, methods of use, and methods of making
|
|
KR20120127754A
(ko)
|
2004-12-20 |
2012-11-23 |
제넨테크, 인크. |
Ｉａｐ의 피롤리딘 억제제
|
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
|
CA2594318A1
(en)
|
2005-01-12 |
2006-07-20 |
Medarex, Inc. |
Irta-2 antibodies and their uses
|
|
EP2322560B1
(en)
|
2005-03-10 |
2013-09-04 |
Morphotek, Inc. |
Anti-mesothelin antibodies
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
|
CA2604032C
(en)
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
|
|
ES2707152T3
(es)
|
2005-04-15 |
2019-04-02 |
Macrogenics Inc |
Diacuerpos covalentes y usos de los mismos
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
|
EP1726650A1
(en)
|
2005-05-27 |
2006-11-29 |
Universitätsklinikum Freiburg |
Monoclonal antibodies and single chain antibody fragments against cell-surface prostate specific membrane antigen
|
|
AU2006259536A1
(en)
|
2005-06-15 |
2006-12-28 |
Schering Corporation |
Anti-IGF1R antibody formulations
|
|
CA2612241C
(en)
|
2005-07-01 |
2018-11-06 |
Medarex, Inc. |
Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
|
|
EP1901091B1
(en)
|
2005-07-04 |
2013-08-21 |
Nikon Vision Co., Ltd. |
Distance measuring apparatus
|
|
WO2007014011A2
(en)
|
2005-07-21 |
2007-02-01 |
Ardea Biosciences, Inc. |
N-(arylamino)-sulfonamide inhibitors of mek
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
JP5364870B2
(ja)
|
2005-08-19 |
2013-12-11 |
アッヴィ・インコーポレイテッド |
二重可変ドメイン免疫グロブリン及びその使用
|
|
ATE452913T1
(de)
|
2005-08-26 |
2010-01-15 |
Pls Design Gmbh |
Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen
|
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
|
JP5102772B2
(ja)
|
2005-11-29 |
2012-12-19 |
ザ・ユニバーシティ・オブ・シドニー |
デミボディ：二量体化活性化治療剤
|
|
EP1960434B1
(en)
|
2005-12-08 |
2012-07-11 |
Medarex, Inc. |
Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
|
|
EP1806365A1
(en)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
|
|
EP1984505B1
(en)
|
2006-01-13 |
2019-12-25 |
The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health |
Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
|
|
EA200870265A1
(ru)
|
2006-02-15 |
2009-02-27 |
Имклоун Системз Инкорпорейтед |
Функционально активные антитела
|
|
CN103073639A
(zh)
|
2006-03-17 |
2013-05-01 |
比奥根艾迪克Ma公司 |
稳定的多肽组合物
|
|
EP1996716B1
(en)
|
2006-03-20 |
2011-05-11 |
The Regents of the University of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
|
WO2007112362A2
(en)
|
2006-03-24 |
2007-10-04 |
The Regents Of The University Of California |
Construction of a multivalent scfv through alkyne-azide 1,3-dipolar cycloaddition
|
|
WO2007110205A2
(en)
|
2006-03-24 |
2007-10-04 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
JP5165672B2
(ja)
|
2006-03-29 |
2013-03-21 |
キングス カレッジ ロンドン |
Ｔｓｈｒに対するアゴニスト抗体
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
DK2010528T3
(en)
|
2006-04-19 |
2018-01-15 |
Novartis Ag |
6-O-Substituted Benzoxazole and Benzothiazole Compounds and Methods for Inhibiting CSF-1R Signaling
|
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之ｃ-ｋｉｔ抗體
|
|
AU2007248019B2
(en)
|
2006-05-03 |
2012-10-11 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Chimeric T cell receptors and related materials and methods of use
|
|
WO2008011216A2
(en)
|
2006-05-16 |
2008-01-24 |
Pro-Pharmaceuticals, Inc. |
Galactose-pronged polysaccharides in a formulation for antifibrotic therapies
|
|
EP2799449A1
(en)
|
2006-05-25 |
2014-11-05 |
Bayer Intellectual Property GmbH |
Dimeric molecular complexes
|
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
|
CN105837690A
(zh)
|
2006-06-12 |
2016-08-10 |
新兴产品开发西雅图有限公司 |
具有效应功能的单链多价结合蛋白
|
|
JP5959795B2
(ja)
|
2006-08-18 |
2016-08-02 |
アーメイゲン・テクノロジーズ・インコーポレイテッドＡｒｍａｇｅｎ Ｔｅｃｈｎｏｌｏｇｉｅｓ， Ｉｎｃ． |
血液脳関門送達のための物質
|
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
|
WO2008040362A2
(en)
|
2006-10-04 |
2008-04-10 |
Københavns Universitet |
Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
|
|
FR2906808B1
(fr)
|
2006-10-10 |
2012-10-05 |
Univ Nantes |
Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
|
|
BRPI0716680A2
(pt)
|
2006-11-02 |
2013-09-24 |
Daniel J Capon |
"composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo"
|
|
RU2009123525A
(ru)
|
2006-11-23 |
2010-12-27 |
Новартис АГ (CH) |
ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
|
|
WO2008061740A1
(en)
|
2006-11-23 |
2008-05-29 |
Novartis Ag |
Pyrimidines and their use as cxcr2 receptor antagonists
|
|
EP2094697A1
(en)
|
2006-11-23 |
2009-09-02 |
Novartis AG |
5-sulfanylmethyl-pyrazolo [1,5-a]pyrimidin-7-ol derivatives as cxcr2 antagonists
|
|
WO2008101234A2
(en)
|
2007-02-16 |
2008-08-21 |
Sloan-Kettering Institute For Cancer Research |
Anti ganglioside gd3 antibodies and uses thereof
|
|
US7635753B2
(en)
|
2007-02-19 |
2009-12-22 |
Wisconsin Alumni Research Foundation |
Prostate cancer and melanoma antigens
|
|
CN104497143B
(zh)
|
2007-03-29 |
2020-08-25 |
健玛保 |
双特异性抗体及其制造方法
|
|
EP2144935A2
(en)
|
2007-03-29 |
2010-01-20 |
Technion Research & Development Foundation Ltd. |
Antibodies, methods and kits for diagnosing and treating melanoma
|
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
|
CA2682605A1
(en)
|
2007-04-18 |
2008-10-30 |
Zymogenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
NZ598890A
(en)
|
2007-04-30 |
2013-10-25 |
Genentech Inc |
Inhibitors of iap
|
|
DK2160401T3
(da)
|
2007-05-11 |
2014-10-20 |
Altor Bioscience Corp |
Fusionsmolekyler og il-15-varianter
|
|
JP2010190572A
(ja)
|
2007-06-01 |
2010-09-02 |
Sapporo Medical Univ |
ＩＬ１３Ｒａ２に対する抗体およびこれを含む診断・治療薬
|
|
KR101586617B1
(ko)
|
2007-06-18 |
2016-01-20 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
|
|
CA2694990A1
(en)
|
2007-07-31 |
2009-02-05 |
Merck Sharp & Dohme Corp. |
Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
|
|
US20090155275A1
(en)
|
2007-07-31 |
2009-06-18 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
ES2628395T3
(es)
|
2007-08-15 |
2017-08-02 |
Bayer Pharma Aktiengesellschaft |
Anticuerpo regulado por proteasa
|
|
AU2008298948B2
(en)
|
2007-09-12 |
2014-09-04 |
F. Hoffmann-La Roche Ag |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
SI2195017T1
(sl)
|
2007-10-01 |
2015-01-30 |
Bristol-Myers Squibb Company |
Človeška protitelesa, ki vežejo mezotelin in njihova uporaba
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
EP2214675B1
(en)
|
2007-10-25 |
2013-11-20 |
Genentech, Inc. |
Process for making thienopyrimidine compounds
|
|
HUE027358T2
(en)
|
2007-11-26 |
2016-09-28 |
Bayer Ip Gmbh |
Anti-mesothelin antibodies and their applications
|
|
WO2009068631A1
(en)
|
2007-11-27 |
2009-06-04 |
Ablynx N.V. |
Method for obtaining polypeptide constructs comprising two or more single domain antibodies
|
|
EP2222709B1
(en)
|
2007-11-30 |
2016-11-23 |
Glaxo Group Limited |
Antigen-binding constructs
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
RU2531758C2
(ru)
|
2008-02-11 |
2014-10-27 |
Куретек Лтд. |
Моноклональные антитела для лечения опухолей
|
|
BRPI0908529A2
(pt)
|
2008-02-26 |
2015-09-29 |
Novartis Ag |
composto orgânicos
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
AR071891A1
(es)
|
2008-05-30 |
2010-07-21 |
Imclone Llc |
Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
|
|
US8168784B2
(en)
|
2008-06-20 |
2012-05-01 |
Abbott Laboratories |
Processes to make apoptosis promoters
|
|
GB0906579D0
(en)
|
2009-04-16 |
2009-05-20 |
Vernalis R&D Ltd |
Pharmaceuticals, compositions and methods of making and using the same
|
|
UA103198C2
(en)
|
2008-08-04 |
2013-09-25 |
Новартис Аг |
Squaramide derivatives as cxcr2 antagonists
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EA019094B1
(ru)
|
2008-08-22 |
2014-01-30 |
Новартис Аг |
Пирролопиримидины и их применение
|
|
JP2012500652A
(ja)
|
2008-08-25 |
2012-01-12 |
アンプリミューン、インコーポレーテッド |
標的化共刺激ポリペプチドおよび癌を処置するための使用方法
|
|
ES2545609T3
(es)
|
2008-08-25 |
2015-09-14 |
Amplimmune, Inc. |
Composiciones de antagonistas de PD-1 y métodos de uso
|
|
CA2736829C
(en)
|
2008-09-12 |
2018-02-27 |
Isis Innovation Limited |
Pd-1 specific antibodies and uses thereof
|
|
WO2010033866A2
(en)
|
2008-09-19 |
2010-03-25 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
|
|
PL2342226T3
(pl)
|
2008-09-26 |
2017-01-31 |
Dana-Farber Cancer Institute, Inc. |
Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
|
|
WO2010063802A1
(en)
|
2008-12-05 |
2010-06-10 |
Novartis Ag |
3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
|
|
EP4209510B1
(en)
|
2008-12-09 |
2024-01-31 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
EP2210891A1
(en)
|
2009-01-26 |
2010-07-28 |
Domain Therapeutics |
New adenosine receptor ligands and uses thereof
|
|
EP3192811A1
(en)
|
2009-02-09 |
2017-07-19 |
Université d'Aix-Marseille |
Pd-1 antibodies and pd-l1 antibodies and uses thereof
|
|
HUE025704T2
(en)
|
2009-03-20 |
2016-04-28 |
Sigma Tau Ind Farmaceuti |
Oxidized triazolyl purine derivatives used as adenosine A2A receptor ligands and their use as medicaments
|
|
CA2757382A1
(en)
|
2009-04-01 |
2010-10-21 |
Kristi Elkins |
Anti-fcrh5 antibodies and immunoconjugates
|
|
BRPI1012560A2
(pt)
|
2009-04-01 |
2016-07-26 |
Genentech Inc |
anticorpos anti-fcrh5 e imunoconjugados e métodos de uso
|
|
AU2010245011B2
(en)
|
2009-04-27 |
2015-09-03 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
JP5694923B2
(ja)
|
2009-04-27 |
2015-04-01 |
協和発酵キリン株式会社 |
血液腫瘍治療を目的とした抗ＩＬ−３Ｒα抗体
|
|
JO3257B1
(ar)
|
2009-09-02 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات كمعدلات لفاعلية tlr
|
|
PT3023438T
(pt)
|
2009-09-03 |
2020-05-08 |
Merck Sharp & Dohme |
Anticorpos anti-gitr
|
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
|
NO2504364T3
(enExample)
|
2009-11-24 |
2018-01-06 |
|
|
|
MX337600B
(es)
|
2009-12-02 |
2016-03-11 |
Imaginab Inc |
Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antigeno de membrana especifico para prostata de humano (psma) y metodos para su uso.
|
|
WO2011076922A1
(en)
|
2009-12-23 |
2011-06-30 |
Synimmune Gmbh |
Anti-flt3 antibodies and methods of using the same
|
|
DK2531492T3
(en)
|
2010-02-05 |
2016-07-04 |
Heptares Therapeutics Ltd |
1,2,4-triazin-4-amine derivatives
|
|
AR080301A1
(es)
|
2010-02-24 |
2012-03-28 |
Immunogen Inc |
Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
|
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
ES2365960B1
(es)
|
2010-03-31 |
2012-06-04 |
Palobiofarma, S.L |
Nuevos antagonistas de los receptores de adenosina.
|
|
JP6040148B2
(ja)
|
2010-04-20 |
2016-12-07 |
ゲンマブ エー／エス |
ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法
|
|
HUE033581T2
(hu)
|
2010-06-10 |
2017-12-28 |
Seragon Pharmaceuticals Inc |
Ösztrogén receptor modulátorok és alkalmazásaik
|
|
WO2011155607A1
(ja)
|
2010-06-11 |
2011-12-15 |
協和発酵キリン株式会社 |
抗ｔｉｍ－３抗体
|
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
|
US8853423B2
(en)
|
2010-06-17 |
2014-10-07 |
Seragon Pharmaceuticals, Inc. |
Indane estrogen receptor modulators and uses thereof
|
|
CA2802344C
(en)
|
2010-06-18 |
2023-06-13 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
|
|
ES2961381T3
(es)
|
2010-06-19 |
2024-03-11 |
Memorial Sloan Kettering Cancer Center |
Anticuerpos anti-GD2
|
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
|
WO2012033885A1
(en)
|
2010-09-08 |
2012-03-15 |
Baylor College Of Medicine |
Immunotherapy of cancer using genetically engineered gd2-specific t cells
|
|
GB2483736B
(en)
|
2010-09-16 |
2012-08-29 |
Aragon Pharmaceuticals Inc |
Estrogen receptor modulators and uses thereof
|
|
EA037063B1
(ru)
|
2010-11-08 |
2021-02-01 |
Аблинкс Н.В. |
Cxcr2-связывающие полипептиды
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
AU2012236068A1
(en)
|
2011-04-01 |
2013-10-17 |
Eureka Therapeutics, Inc. |
T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
|
|
SI2699264T1
(en)
|
2011-04-20 |
2018-08-31 |
Medimmune Llc |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
AR086044A1
(es)
|
2011-05-12 |
2013-11-13 |
Imclone Llc |
Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
|
|
SI3415531T1
(sl)
|
2011-05-27 |
2023-12-29 |
Glaxo Group Limited |
Bcma (cd269/tnfrsf17) - vezni proteini
|
|
EP2537933A1
(en)
|
2011-06-24 |
2012-12-26 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
An IL-15 and IL-15Ralpha sushi domain based immunocytokines
|
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
|
EP2760821B1
(en)
|
2011-09-02 |
2017-10-11 |
Novartis AG |
Choline salt of an anti-inflammatory substituted cyclobutenedione compound
|
|
EP2755487B1
(en)
|
2011-09-16 |
2018-12-19 |
Baylor College Of Medicine |
Targeting the tumor microenvironment using manipulated nkt cells
|
|
US10421960B2
(en)
|
2011-09-16 |
2019-09-24 |
The Trustees Of The University Of Pennsylvania |
RNA engineered T cells for the treatment of cancer
|
|
ITMO20110270A1
(it)
|
2011-10-25 |
2013-04-26 |
Sara Caldrer |
Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
|
|
DK2771364T3
(da)
|
2011-10-27 |
2019-08-19 |
Genmab As |
Fremstilling af heterodimere proteiner
|
|
US9272002B2
(en)
|
2011-10-28 |
2016-03-01 |
The Trustees Of The University Of Pennsylvania |
Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
|
WO2013074916A1
(en)
|
2011-11-18 |
2013-05-23 |
Board Of Regents, The University Of Texas System |
Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
|
|
US9624298B2
(en)
|
2011-11-28 |
2017-04-18 |
Merck Patent Gmbh |
Anti-PD-L1 antibodies and uses thereof
|
|
US9439768B2
(en)
|
2011-12-08 |
2016-09-13 |
Imds Llc |
Glenoid vault fixation
|
|
EP3594245A1
(en)
|
2012-02-13 |
2020-01-15 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
KR20140127816A
(ko)
|
2012-02-22 |
2014-11-04 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
암의 치료에 유용한 t 세포의 지속성 집단을 생성시키기 위한 조성물 및 방법
|
|
CA2868121C
(en)
|
2012-03-23 |
2021-06-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
BR112014027166A2
(pt)
|
2012-05-01 |
2017-06-27 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
ES2924722T3
(es)
|
2012-05-18 |
2022-10-10 |
Aptevo Res & Development Llc |
Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
|
|
WO2013179174A1
(en)
|
2012-05-29 |
2013-12-05 |
Koninklijke Philips N.V. |
Lighting arrangement
|
|
AU2013267161A1
(en)
|
2012-05-31 |
2014-11-20 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
WO2014022758A1
(en)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
|
|
PL3824905T3
(pl)
|
2012-08-20 |
2025-05-05 |
Fred Hutchinson Cancer Center |
Sposób i kompozycje do immunoterapii komórkowej
|
|
WO2014043708A1
(en)
|
2012-09-17 |
2014-03-20 |
Traber Peter G |
Method for enhancing specific immunotherapies in cancer treatment
|
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
|
WO2014066527A2
(en)
|
2012-10-24 |
2014-05-01 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Ｂｃｍａ抗原結合蛋白質
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9963513B2
(en)
|
2013-02-05 |
2018-05-08 |
Engmab Sàrl |
Method for the selection of antibodies against BCMA
|
|
HUE039052T2
(hu)
|
2013-02-19 |
2018-12-28 |
Novartis Ag |
Benzotiofénszármazékok és azok készítményei szelektív ösztrogén receptor lebontóként
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
LT2958943T
(lt)
|
2013-02-20 |
2020-01-27 |
The Trustees Of The University Of Pennsylvania |
Vėžio gydymas, naudojant humanizuotą anti-egfrviii chimerinio antigeno receptorių
|
|
WO2014138819A1
(en)
|
2013-03-14 |
2014-09-18 |
Csl Limited |
Agents that neutralize il-3 signaling and uses thereof
|
|
WO2014138805A1
(en)
|
2013-03-14 |
2014-09-18 |
Csl Limited |
Anti il-3r alpha agents and uses thereof
|
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res Munich Gmbh |
Moléculas de unión para bcma y cd3
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
US10280221B2
(en)
|
2013-03-15 |
2019-05-07 |
Glaxosmithkline Intellectual Property Development Limited |
Anti-LAG-3 binding proteins
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
WO2014165707A2
(en)
|
2013-04-03 |
2014-10-09 |
Memorial Sloan-Kettering Cancer Center |
Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
|
|
JP6742903B2
(ja)
|
2013-05-02 |
2020-08-19 |
アナプティスバイオ インコーポレイティッド |
プログラム死−１（ｐｄ−１）に対する抗体
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
TWI725931B
(zh)
|
2013-06-24 |
2021-05-01 |
美商建南德克公司 |
抗ｆｃｒｈ５抗體
|
|
US20160145355A1
(en)
|
2013-06-24 |
2016-05-26 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
|
AR097306A1
(es)
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
LT3702373T
(lt)
|
2013-09-13 |
2022-11-10 |
Beigene Switzerland Gmbh |
Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
|
|
AU2014339900B2
(en)
|
2013-10-25 |
2019-10-24 |
Dana-Farber Cancer Institute, Inc. |
Anti-PD-L1 monoclonal antibodies and fragments thereof
|
|
WO2015081158A1
(en)
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
|
HUE046249T2
(hu)
|
2013-12-12 |
2020-02-28 |
Shanghai hengrui pharmaceutical co ltd |
PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
|
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3094351B9
(en)
|
2014-01-15 |
2022-04-13 |
Kadmon Corporation, LLC |
Immunomodulatory agents
|
|
CA2936244A1
(en)
|
2014-01-21 |
2015-07-30 |
Medimmune, Llc |
Compositions and methods for modulating and redirecting immune responses
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
CA2935423C
(en)
|
2014-01-24 |
2023-11-07 |
Dana-Farber Cancer Institute, Inc. |
Antibody molecules to pd-1 and uses thereof
|
|
PT3556775T
(pt)
|
2014-01-28 |
2021-12-31 |
Bristol Myers Squibb Co |
Anticorpos anti-lag-3 para tratar neoplasias malignas hematológicas
|
|
AU2015210750B2
(en)
|
2014-01-31 |
2020-08-20 |
Children's Medical Center Corporation |
Antibody molecules to TIM-3 and uses thereof
|
|
US9855270B2
(en)
|
2014-03-13 |
2018-01-02 |
Genentech, Inc. |
Methods and compositions for modulating estrogen receptor mutants
|
|
WO2015138920A1
(en)
|
2014-03-14 |
2015-09-17 |
Novartis Ag |
Antibody molecules to lag-3 and uses thereof
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
|
DK3149042T3
(da)
|
2014-05-29 |
2019-11-04 |
Spring Bioscience Corp |
PD-L1-antistoffer og anvendelser deraf
|
|
AU2015271709B2
(en)
|
2014-06-06 |
2020-11-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
TWI726608B
(zh)
|
2014-07-03 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
MY181834A
(en)
|
2014-07-21 |
2021-01-08 |
Novartis Ag |
Treatment of cancer using humanized anti-bcma chimeric antigen receptor
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
MX2017001079A
(es)
|
2014-07-24 |
2017-09-12 |
Bluebird Bio Inc |
Receptores de antígeno quiméricos de antígeno de maduración de células b (bcma).
|
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
RU2017115315A
(ru)
|
2014-10-03 |
2018-11-08 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
WO2016061142A1
(en)
|
2014-10-14 |
2016-04-21 |
Novartis Ag |
Antibody molecules to pd-l1 and uses thereof
|
|
ES2763548T3
(es)
|
2014-11-06 |
2020-05-29 |
Hoffmann La Roche |
Anticuerpos anti-TIM3 y procedimientos de uso
|
|
US20160129108A1
(en)
|
2014-11-11 |
2016-05-12 |
Medimmune Limited |
Therapeutic combinations comprising anti-cd73 antibodies and uses thereof
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗ｐｄ－１抗體類和使用彼等之方法
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
CN107922484A
(zh)
|
2015-03-06 |
2018-04-17 |
索伦托治疗有限公司 |
结合tim3的抗体治疗剂
|
|
EP3277321B1
(en)
|
2015-04-01 |
2024-08-14 |
AnaptysBio, Inc. |
Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
|
|
JP6812364B2
(ja)
|
2015-06-03 |
2021-01-13 |
ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ |
癌診断用抗ｇｉｔｒ抗体
|
|
CN108650886B
(zh)
|
2015-07-23 |
2022-07-05 |
英伊布里克斯公司 |
多价和多特异性gitr-结合融合蛋白
|
|
US10561653B2
(en)
|
2015-08-11 |
2020-02-18 |
Novartis Ag |
5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
|
|
WO2017025610A1
(en)
|
2015-08-12 |
2017-02-16 |
Medimmune Limited |
Gitrl fusion proteins and uses thereof
|
|
MX2018001814A
(es)
|
2015-08-13 |
2018-05-07 |
Merck Sharp & Dohme |
Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
|
|
JOP20190221A1
(ar)
|
2017-04-05 |
2019-09-23 |
Seal Rock Therapeutics Inc |
مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
|
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
WO2019060693A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
KR20200086278A
(ko)
*
|
2017-10-18 |
2020-07-16 |
노파르티스 아게 |
선택적 단백질 분해를 위한 조성물 및 방법
|
|
US20230045737A1
(en)
*
|
2018-12-05 |
2023-02-09 |
Vividion Therapeutics, Inc. |
Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
|
|
US20220306659A1
(en)
*
|
2019-08-23 |
2022-09-29 |
Beijing Tide Pharmaceutical Co., Ltd. |
Compound inhibiting and inducing degradation of egfr and alk
|
|
CR20220234A
(es)
*
|
2019-10-30 |
2022-07-19 |
Dana Farber Cancer Inst Inc |
Degradadores de moléculas pequeñas de helios y procedimientos de uso
|
|
KR20220103753A
(ko)
*
|
2019-11-19 |
2022-07-22 |
브리스톨-마이어스 스큅 컴퍼니 |
헬리오스 단백질의 억제제로서 유용한 화합물
|
|
TW202140441A
(zh)
*
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|